PI
CTMX icon

Putnam Investments’s CytomX Therapeutics CTMX Stock Holding History

Putnam Investments’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-74,819
Closed -$1.29M – 1148
2017
Q1 		$1.29M Sell
74,819
-1,289,673
-95% -$17M ﹤0.01% 951
2016
Q4 		$15M Sell
1,364,492
-5,309
-0.4% -$64.3K 0.04% 316
2016
Q3 		$21.5M Buy
1,369,801
+1,044,801
+321% +$12.6M 0.05% 266
2016
Q2 		$3.32M Hold
325,000
– – 0.01% 789
2016
Q1 		$4.19M Hold
325,000
– – 0.01% 700
2015
Q4 		$6.78M Buy
+325,000
New +$5.14M 0.02% 563

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Putnam Investments's CTMX Position: Q2 2017 in Review

Putnam Investments sold out of CytomX Therapeutics (CTMX) in Q2 2017, closing a stake of 74,819 shares — an estimated $1.29M sold.

Putnam Investments first reported a position in CTMX in Q4 2015 and held it in 6 quarters. The position peaked at $21.5M in Q3 2016. 90 funds tracked by Wall St. Rank hold CTMX as of Q2 2017.

  • Putnam Investments reported no remaining CytomX Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Putnam Investments sold 74,819 CytomX Therapeutics shares in Q2 2017, an estimated $1.29M.
  • Putnam Investments first reported a position in CytomX Therapeutics in Q4 2015 and held it in 6 quarters.
  • Putnam Investments's CytomX Therapeutics position peaked at $21.5M in Q3 2016.
  • 90 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2017.

Based on Putnam Investments's 13F filing for Q2 2017, filed 14 Aug 2017.